Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes switched from glinides

Journal of Diabetes Investigation

Volumn 5, Issue 2, 2014, Pages 199-205

  Tanaka, Tsuyoshi ^a   Goto, Hiroyuki ^a   Araki, Rika ^a   Yamamoto, Mika ^a   Tanaka, Takashi ^a   Fujiwara, Ryoko ^b   Murata, Kazuya ^b  

^a National Hospital Organization Mie Chuo Medical Center   (Japan)

^b ISE RED CROSS HOSPITAL   (Japan)

Author keywords

Glinides; Sitagliptin; Type 2 diabetes

Indexed keywords

1,5 ANHYDROSORBITOL; GLUCAGON; GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; MITIGLINIDE; NATEGLINIDE; PIOGLITAZONE; SITAGLIPTIN;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CELL FUNCTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; JAPANESE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84896490345     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12140     Document Type: Article

References (23)

1. Creutzfeldt W. The [pre-] history of the incretin concept. Regul Pept 2005; 128: 87-91.
2. Nauck MA, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52.
3. Nauck MA, Kleine N, Ørskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
4. Creutzfeldt W. The entero-insular axis in type 2 diabetes - incretins as therapeutic agents. Exp Clin Endocrinol Diabetes 2001; 109(Suppl 2): S288-S303.
5. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20: 876-913.
6. Ahrén B. Gut peptides and type 2 diabetes mellitus treatment. Curr Diab Rep 2003; 3: 365-372.
7. Drucker DJ, Bergenstal RM, Sherman SI, et al. Incretin-Based Therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010; 33: 428-433.
8. Iwamoto Y, Tajima N, Kadowaki T, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes. a randomized, double-blind trial. Diabetes Obes Metab 2010; 12: 613-622.
9. Seino Y, Fujita T, Hiroi S, et al. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin 2011; 27: 1781-1792.
10. Kaku K, Tanaka S, Origasa H, et al. Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial. Endocr J 2009; 56: 657-664.
11. Nonaka K, Tsubouchi H, Okuyama K, et al. Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus. Horm Metab Res 2009; 41: 232-237.
12. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy compared in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008; 79: 291-298.
13. Iwamoto Y, Taniguchi T, Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 2010; 57: 383-394.
14. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 2012; 3: 39-40.
15. Yamada Y, Fukuda K, Fujimoto S, et al. SUIT, secretory units of islets in transplantation: an index for therapeutic management of islet transplanted patients and its application to type 2 diabetes. Diabetes Res Clin Pract 2006; 74: 222-226.
16. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612-4619.
17. Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007; 92: 1249-1255.
18. Rosenstock J, Foly JE, Rendell M, et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008; 31: 30-35.
19. Hare KJ, Vilsboll T, Asmar M, et al. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 2010; 59: 1765-1770.
20. Riche DM, East HE, Riche KD. Impact of sitagliptin on markers of β-cell function: a meta-analysis. Am J Med Sci 2009; 337: 321-328.
21. Farilla L, Bulotta A, Hirsheberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149-5158.
22. Mu J, Woods J, Zhou Y, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695-1704.
23. Odawara M, Kadowaki T, Tajima N, et al. Long-term safety, tolerability, and efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetol Int 2011; 2: 94-105.